---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-024270"
form_type: "8-K"
ticker: "CNTN"
cik: "0001861657"
company_name: "Canton Strategic Holdings, Inc."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T10:16:11.984743+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Hillstream BioPharma signs ABSI license for ErbB2/ErbB3; appoints Sireesh Appajosyula as COO

## Summary
- Licensed exclusive rights from ABSI to develop antibodies targeting ErbB2 (Her2) and ErbB3 in all human/animal diseases worldwide.
- Will issue $250k in common stock to ABSI within 30 days; milestones up to $8.25M; royalties low-to-mid single digits on net sales.
- Appointed director Sireesh Appajosyula as COO effective July 6, 2023; base salary $400k, annual bonus target 50% of base.
- Amended CEO Randy Milby's employment: base $500k, bonus target 60%, severance period increased to 18 months on certain terminations.

## SEC filing metadata
- accession: 0001493152-23-024270
- form_type: 8-K
- ticker: CNTN
- cik: 0001861657
- company_name: Canton Strategic Holdings, Inc.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861657/000149315223024270/0001493152-23-024270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861657/000149315223024270/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-024270
- JSON: https://secwatch.observer/filing/0001493152-23-024270.json
- Plain text: https://secwatch.observer/filing/0001493152-23-024270.txt

## Key facts
- Executive change
  Sireesh Appajosyula was appointed as Chief Operating Officer at Canton Strategic Holdings, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On July 6, 2023, the Board appointed Sireesh Appajosyula, the Company’s director, as Chief Operating Officer of the Company effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861657/000149315223024270/0001493152-23-024270-index.htm
- Material Agreements
  Canton Strategic Holdings, Inc. entered into ABSI Agreement with Applied Biomedical Science Institute (ABSI) valued at $250,000 (effective 2023-07-05).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Applied Biomedical Science Institute (ABSI)
  - Value: $250,000
  - Effective: 2023-07-05
  source text: On July 5, 2023 (the “ABSI Effective Date”), Hillstream BioPharma, Inc. (the “Company”) entered into a Research and Development Collaboration and License Agreement (the “ABSI Agreement”) with Applied Biomedical Science Institute (“ABSI”) pursuant to which ABSI granted the Company an exclusive royalty-bearing, sublicensable license to the ABSI Patents
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861657/000149315223024270/0001493152-23-024270-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.